B-J Ko1, S M Kim2, K H Park3, H S Park4, C S Mantzoros5. 1. 1] Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA [2] Department of Family Medicine, College of Medicine, Korea University, Seoul, Korea. 2. Department of Family Medicine, College of Medicine, Korea University, Seoul, Korea. 3. 1] Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA [2] Department of Family Medicine, Hallym University Sacred Heart Hospital, Hallym University, Gyeonggi-do, Korea. 4. Department of Family Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 5. 1] Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA [2] Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND/ OBJECTIVES: Circulating selenoprotein P (SeP), fibroblast growth factor (FGF) 21 and FGF23 have been associated with metabolic syndrome (MetS) in adults but not in children. We sought to evaluate the association among SeP, FGF21, FGF23 and MetS in young children. SUBJECTS/ METHODS: A cross-sectional study conducted during a school health examination on 210 children aged 9 years. We measured serum SeP, FGF21 and FGF23 levels, and assessed anthropometric and cardiometabolic variables. MetS was defined as the presence of ⩾3 of the following five criteria: high blood pressure, low high-density lipoprotein cholesterol (HDL-C), high triglyceride, high fasting glucose and abdominal obesity. RESULTS: SeP was correlated positively with HDL-C and negatively with body mass index, waist circumference (WC), blood pressure, transaminases, triglyceride and homeostasis model assessment of insulin resistance (HOMA-IR). FGF21 was directly correlated with WC, triglyceride and HOMA-IR, and FGF23 was inversely correlated with fasting glucose and alanine aminotransferase. Children with MetS had lower SeP and FGF23 levels and higher HOMA-IR than children without MetS. The highest tertile of SeP had decreased odds for MetS (odds ratio 0.05, 95% confidence interval (CI) 0.00-0.96, P for trend=0.042), whereas FGF21 and FGF23 did not relate to the risk for MetS after controlling for confounders. CONCLUSIONS: Elevated SeP concentrations are independently associated with a reduced risk of MetS in children. The associations between FGF21, FGF23 and metabolic parameters are not of comparable significance.
BACKGROUND/ OBJECTIVES: Circulating selenoprotein P (SeP), fibroblast growth factor (FGF) 21 and FGF23 have been associated with metabolic syndrome (MetS) in adults but not in children. We sought to evaluate the association among SeP, FGF21, FGF23 and MetS in young children. SUBJECTS/ METHODS: A cross-sectional study conducted during a school health examination on 210 children aged 9 years. We measured serum SeP, FGF21 and FGF23 levels, and assessed anthropometric and cardiometabolic variables. MetS was defined as the presence of ⩾3 of the following five criteria: high blood pressure, low high-density lipoprotein cholesterol (HDL-C), high triglyceride, high fasting glucose and abdominal obesity. RESULTS:SeP was correlated positively with HDL-C and negatively with body mass index, waist circumference (WC), blood pressure, transaminases, triglyceride and homeostasis model assessment of insulin resistance (HOMA-IR). FGF21 was directly correlated with WC, triglyceride and HOMA-IR, and FGF23 was inversely correlated with fasting glucose and alanine aminotransferase. Children with MetS had lower SeP and FGF23 levels and higher HOMA-IR than children without MetS. The highest tertile of SeP had decreased odds for MetS (odds ratio 0.05, 95% confidence interval (CI) 0.00-0.96, P for trend=0.042), whereas FGF21 and FGF23 did not relate to the risk for MetS after controlling for confounders. CONCLUSIONS: Elevated SeP concentrations are independently associated with a reduced risk of MetS in children. The associations between FGF21, FGF23 and metabolic parameters are not of comparable significance.
Authors: Kyung M Choi; Mary Yannakoulia; Min S Park; Geum J Cho; Jung H Kim; Seung H Lee; Taik G Hwang; Sei J Yang; Tai N Kim; Hye J Yoo; Sai H Baik; Seon M Kim; Christos S Mantzoros Journal: Am J Clin Nutr Date: 2010-11-24 Impact factor: 7.045
Authors: Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu Journal: Diabetes Date: 2008-02-05 Impact factor: 9.461
Authors: D Sánchez-Infantes; J M Gallego-Escuredo; M Díaz; G Aragonés; G Sebastiani; A López-Bermejo; F de Zegher; P Domingo; F Villarroya; L Ibáñez Journal: Int J Obes (Lond) Date: 2015-01-20 Impact factor: 5.095
Authors: Romina di Giuseppe; Manja Koch; Ute Nöthlings; Gabi Kastenmüller; Anna Artati; Jerzy Adamski; Gunnar Jacobs; Wolfgang Lieb Journal: Endocrine Date: 2018-11-17 Impact factor: 3.633
Authors: Lorena Del Rocío Ibarra-Reynoso; Liudmila Pisarchyk; Elva Leticia Pérez-Luque; Ma Eugenia Garay-Sevilla; Juan Manuel Malacara Journal: Nutr Metab (Lond) Date: 2015-09-15 Impact factor: 4.169
Authors: Anna Baran; Julia Nowowiejska; Julita Anna Krahel; Tomasz W Kaminski; Magdalena Maciaszek; Iwona Flisiak Journal: Int J Mol Sci Date: 2020-06-28 Impact factor: 5.923
Authors: Alexey A Tinkov; Olga P Ajsuvakova; Tommaso Filippini; Ji-Chang Zhou; Xin Gen Lei; Eugenia R Gatiatulina; Bernhard Michalke; Margarita G Skalnaya; Marco Vinceti; Michael Aschner; Anatoly V Skalny Journal: Biomolecules Date: 2020-04-24
Authors: Eleni M Domouzoglou; Antonios P Vlahos; Vasileios K Cholevas; Michail I Papafaklis; Nikolaos Chaliasos; Ekaterini Siomou; Lampros K Michalis; Agathocles Tsatsoulis; Katerina K Naka Journal: Ann Pediatr Endocrinol Metab Date: 2021-05-17